Back to search results

Exosome-Based Liquid Biopsy for Liver Cancer Diagnosis

This observational study is developing a new diagnostic test called ELUCIDATE to help doctors tell the difference between two types of primary liver cancer: hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). It can be difficult to tell these cancers apart before surgery, but they need different treatments. Researchers will analyze blood samples to look at tiny particles called exosomes, which carry information about the cancer. The goal is to see how well ELUCIDATE can accurately identify each type of liver cancer. You may be able to join if you are 18 or older, have a confirmed diagnosis of HCC or ICC, and have a blood sample available from before treatment.

Study design
This is an observational study planning to enroll 400 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study measures sensitivity through study completion, an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06342414

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

Recruiting
Not specifiedAges 18+Observational
City of Hope Medical Center
~400 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:ELUCIDATE

At a glance

Recruiting sites
5 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sensitivity
Measured over Through study completion, an average of 1 year

Conditions

Hepatocellular Carcinoma
Intrahepatic Cholangiocarcinoma
Cholangiocarcinoma
Primary Liver Cancer
Primary Liver Carcinoma
Hepatic Cancer
Hepatic Carcinoma

Explore related trials

Hepatocellular CarcinomaIntrahepatic Cholangiocarcinoma

NCT06342414

Where you'd take part

This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope Medical Center

    Duarte, Californiastudy coordinator listed

    Recruiting

  • Graduate School of Medical Sciences, Kumamoto University

    Kumamoto, Japanno site contact published

    Recruiting

  • Graduate School of Medical Sciences, Kyushu University

    Fukuoka, Japanno site contact published

    Recruiting

  • Hokkaido University Graduate School of Medicine

    Sapporo, Japanno site contact published

    Recruiting

  • Tokushima University

    Tokushima, Japanno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Ajay Goel, PhD · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Ajay Goel, PhD
[email protected]
6262183452
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

A histologically confirmed diagnosis of hepatocellular carcinoma
A histologically confirmed diagnosis of intrahepatic cholangiocarcinoma
Received standard diagnostic and staging procedures as per local guidelines
Availability of at least one blood-derived sample, drawn before receiving any curative-intent treatment

Exclusion

Lack of or inability to provide informed consent
Synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma
Primary liver cancer other than hepatocellular carcinoma or intrahepatic cholangiocarcinoma
Secondary liver cancer

What this trial measures

  • SensitivityThrough study completion, an average of 1 year

    True Positive Rate: the probability of a positive test result, conditioned on the individual truly being positive